[{"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-001", "question": "A 38-year-old man undergoes evaluation for chronic diarrhea and weight loss. Small bowel biopsy reveals villous atrophy with increased intraepithelial lymphocytes. Despite strict gluten-free diet adherence confirmed by negative tissue transglutaminase antibodies for 18 months, symptoms persist. Repeat biopsy shows persistent villous atrophy with aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, and CD103, with loss of CD8. T-cell receptor gene rearrangement studies show a monoclonal population. Which therapeutic approach offers the best chance of inducing remission before consideration of autologous stem cell transplantation?", "options": ["Budesonide 9 mg daily", "Cladribine-based chemotherapy", "Infliximab induction and maintenance", "Azathioprine 2.5 mg/kg daily", "Mesalamine 4.8 g daily"], "answer": "B", "answer_index": 1, "explanation": "This patient has Type II refractory celiac disease (RCD II), characterized by aberrant intraepithelial lymphocytes with the described immunophenotype (surface CD3-negative, cytoplasmic CD3-positive, CD8 loss) and monoclonal TCR rearrangement. RCD II has high risk of progression to enteropathy-associated T-cell lymphoma. Cladribine (2-CdA), a purine analog, has shown the best response rates (approximately 40-50%) in inducing histologic and clinical remission in RCD II and serves as a bridge to autologous stem cell transplantation. Steroids, immunomodulators, and biologics used in RCD I are ineffective in RCD II.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "B", "model_outputs": "The patient's clinical presentation and biopsy findings are characteristic of Refractory Celiac Disease Type II (RCD II).\n\n1.  Diagnosis:\n    *   Refractory Celiac Disease: Malabsorption and villous atrophy persist despite strict adherence to a gluten-free diet (confirmed by negative serology) for more than 12 months.\n    *   Type II vs. Type I: The distinction lies in the immunophenotype of the intraepithelial lymphocytes (IELs).\n        *   Type I: Normal phenotype (Surface CD3+, CD8+). Treated similarly to active celiac disease, often with corticosteroids (e.g., budesonide) or immunosuppressants like azathioprine.\n        *   Type II: Aberrant phenotype (Surface CD3-, Cytoplasmic CD3+, CD8-, CD7+, CD103+) and presence of a monoclonal T-cell population (TCR gene rearrangement). This is considered a cryptic T-cell lymphoma or a pre-malignant condition for Enteropathy-Associated T-cell Lymphoma (EATL).\n\n2.  Treatment Analysis:\n    *   Option A (Budesonide): While open-capsule budesonide can provide symptomatic improvement and is sometimes used as a bridge, it rarely induces complete histologic remission or eradicates the aberrant clonal T-cells in RCD II. It is more appropriate for RCD Type I.\n    *   Option B (Cladribine): Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analogue that is toxic to lymphocytes. It is currently the medical therapy with the best evidence for inducing clinical and histological remission in RCD Type II by reducing the burden of the aberrant T-cell clone. It is typically the preferred treatment step before considering more aggressive consolidation therapies like autologous stem cell transplantation (ASCT).\n    *   Option C (Infliximab): Anti-TNF agents are not standard therapy for RCD II and do not target the underlying malignant potential of the aberrant clone.\n    *   Option D (Azathioprine): This is used for RCD Type I. It helps with the inflammatory component but is generally ineffective against the clonal expansion in RCD Type II and allows the pre-malignant cells to persist or progress.\n    *   Option E (Mesalamine): This is used for ulcerative colitis and has no role in investigating or treating refractory celiac disease.\n\nTherefore, Cladribine-based chemotherapy offers the best chance of inducing remission and managing the aberrant clone in RCD Type II.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-002", "question": "A 71-year-old man with COPD GOLD stage III is hospitalized for acute exacerbation. On day 3, despite antibiotics, systemic corticosteroids, and scheduled bronchodilators, he remains dyspneic with respiratory rate 28/min, accessory muscle use, and ABG showing pH 7.31, PaCO2 58 mmHg, PaO2 55 mmHg on 4L nasal cannula. He is alert and cooperative. Bilevel positive airway pressure (BiPAP) is initiated at IPAP 12/EPAP 5 cm H2O. After 2 hours, repeat ABG shows pH 7.29, PaCO2 62 mmHg. He remains tachypneic but is tolerating the mask. What is the most appropriate next step?", "options": ["Increase IPAP to 18 cm H2O and reassess in 1-2 hours", "Proceed with endotracheal intubation and mechanical ventilation", "Add heliox (helium-oxygen mixture) to the BiPAP circuit", "Switch to high-flow nasal cannula at 60 L/min", "Increase EPAP to 10 cm H2O while maintaining IPAP"], "answer": "A", "answer_index": 0, "explanation": "The patient has acute hypercapnic respiratory failure from COPD exacerbation with initial NIV settings that are inadequate (worsening hypercapnia). The driving pressure (IPAP-EPAP = 7 cm H2O) is insufficient for adequate ventilation. Increasing IPAP to 18 cm H2O (driving pressure 13 cm H2O) will augment tidal volume and improve CO2 clearance. Intubation (B) is premature as he is tolerating NIV and is not deteriorating clinically. Heliox (C) reduces airway resistance but doesn't address ventilation. HFNC (D) provides less ventilatory support than BiPAP for hypercapnic failure. Increasing EPAP alone (E) would reduce driving pressure further, worsening ventilation.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "A", "model_outputs": "This patient with GOLD stage III COPD is presenting with an acute exacerbation complicated by acute-on-chronic hypercapnic respiratory failure. He was started on non-invasive positive pressure ventilation (NIPPV/BiPAP) with settings of IPAP 12 cm H2O and EPAP 5 cm H2O.\n\nThe physiological goal in treating hypercapnic respiratory failure is to improve alveolar ventilation to lower the $\\text{PaCO}_2$ and improve the pH. On BiPAP, ventilation is primarily determined by the difference between the Inspiratory Positive Airway Pressure (IPAP) and the Expiratory Positive Airway Pressure (EPAP), known as pressure support (PS). In this case, the pressure support is $12 - 5 = 7$ cm H2O.\n\nAfter 2 hours, the patient has worsening respiratory acidosis ($\\text{pH}$ decreased to 7.29, $\\text{PaCO}_2$ increased to 62 mmHg). This indicates that the current ventilation support is insufficient. However, the patient is alert, cooperative, and tolerating the mask, and the pH is not yet critically low (typically $< 7.25$ indicates severe failure, though clinical context matters). Therefore, there is a window to optimize NIPPV settings before resorting to invasive mechanical ventilation.\n\nTo improve ventilation and blow off $\\text{CO}_2$, the tidal volume must be increased. This is improved by increasing the IPAP, thereby increasing the pressure support ($\\Delta P$). The current IPAP of 12 represents a relatively low level of support. Increasing the IPAP to 18 cm H2O (Option A) would increase the pressure support to 13 cm H2O ($18 - 5$), significantly augmenting tidal volume and assisting with $\\text{CO}_2$ clearance.\n\nOption B (Intubation) is a viable backup if the patient decompensates (e.g., obtundation, hemodynamic instability) or fails to improve despite maximal non-invasive support. However, since the current settings are sub-maximal and the patient is stable and compliant, optimizing NIPPV is the preferred next step to avoid the complications of intubation.\n\nOption C (Heliox) is not a standard first-line rescue maneuver compared to pressure adjustment.\n\nOption D (High-flow nasal cannula) is generally less effective than NIPPV for acute hypercapnic respiratory failure with significant acidosis.\n\nOption E (Increasing EPAP only) would decrease the pressure gradient ($12 - 10 = 2$), leading to a reduction in tidal volume and worsening hypercapnia.\n\nTherefore, the most appropriate step is to increase the ventilatory support.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-003", "question": "A 45-year-old woman from rural Peru presents with a 3-month history of progressive dysphagia, regurgitation, and 20-pound weight loss. Barium swallow shows a dilated esophagus with smooth tapering at the gastroesophageal junction (\"bird's beak\" appearance). Esophageal manometry reveals absent peristalsis and incomplete lower esophageal sphincter relaxation. Serologic testing for Trypanosoma cruzi is positive. Cardiac evaluation shows a dilated left ventricle with apical aneurysm and EF 35%. Which statement best characterizes the pathophysiology linking her esophageal and cardiac findings?", "options": ["Direct parasitic invasion of smooth muscle cells in both organs", "Autoimmune destruction of intramural neurons and cardiac myocytes", "Eosinophilic infiltration causing tissue fibrosis", "Vasculitis affecting the vasa nervorum and coronary arteries", "Toxin-mediated damage similar to diphtheria"], "answer": "B", "answer_index": 1, "explanation": "Chronic Chagas disease (American trypanosomiasis) causes megaesophagus and cardiomyopathy through autoimmune mechanisms. Molecular mimicry between T. cruzi antigens and host cardiac myosin, neuronal proteins, and other self-antigens triggers autoimmune destruction of intramural ganglion cells (Auerbach's plexus) in the esophagus and cardiac myocytes/conduction tissue. The apical aneurysm is pathognomonic for Chagas cardiomyopathy. Direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions. The pathology is characterized by lymphocytic infiltration and fibrosis, not eosinophilia or vasculitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-015", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "B", "model_outputs": "This patient presents with signs and symptoms of Chagas disease (*American trypanosomiasis*), caused by the protozoan parasite *Trypanosoma cruzi*. The clinical picture includes:\n1.  Esophageal involvement: \"Megaesophagus\" (secondary achalasia) characterized by dysphagia, regurgitation, weight loss, and a \"bird's beak\" appearance on barium swallow. This mimics idiopathic achalasia.\n2.  Cardiac involvement: Chronic Chagasic cardiomyopathy, characterized by dilated cardiomyopathy, apical aneurysm (a classic/pathognomonic finding), and conduction abnormalities.\n3.  Epidemiology: Origin from an endemic area (rural Peru).\n\nPathophysiology:\nThe chronic manifestations of Chagas disease develop years after the initial infection. The pathophysiology involves chronic inflammation and fibrosis.\n*   Gastrointestinal Tract: The hallmark of Chagasic megaesophagus (and megacolon) is the destruction of the intramural neurons of the enteric nervous system (specifically the myenteric or Auerbach's plexus). The loss of these neurons leads to the loss of peristalsis and the inability of the lower esophageal sphincter to relax (achalasia).\n*   Heart: The classic lesion involves inflammation, fibrosis, and loss of cardiac myocytes and conduction system pathways.\n\nRegarding the specific options:\n*   Option B correctly identifies the destruction of intramural neurons as the cause of the esophageal findings and cardiac myocytes as the target in the heart. While the exact balance between parasite persistence and autoimmunity (molecular mimicry) is debated in the scientific literature, medical board examinations and standard textbooks frequently describe an autoimmune component or inflammatory destruction of these specific tissue targets as the mechanism for the chronic pathology.\n*   Option A focuses on smooth muscle invasion capable of occurring during the acute phase. However, the specific functional deficit in the esophagus (achalasia) is neuropathic (loss of inhibitory innervation), not myopathic. Therefore, referencing neurons is crucial for the correct answer.\n*   Options C, D, and E describe mechanisms (eosinophilia, vasculitis, toxin) that are not the primary pathophysiologic processes in Chagas disease.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-004", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "topics_mapped", "source_label_raw": "Pediatrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed126.jsonl", "pred": "B", "model_outputs": "In d-transposition of the great arteries (d-TGA), the systemic and pulmonary circulations are arranged in parallel rather than in series. Survival depends entirely on mixing between the two circuits at the atrial level (PFO/ASD), ventricular level (VSD), or great arterial level (PDA).\n\nIn this scenario, the neonate has an intact ventricular septum (no VSD) and a restrictive patent foramen ovale (PFO). Although Prostaglandin E1 (PGE1) has been initiated to maintain ductal patency, the oxygen saturation remains low (55%). In d-TGA with an intact ventricular septum, effective mixing is heavily dependent on the atrial communication. Oxygenated blood returning from the lungs to the left atrium needs to cross to the right atrium to be pumped out to the body by the right ventricle/aorta. A restrictive PFO prevents this flow, leading to severe hypoxemia and potentially left atrial hypertension.\n\nThe most appropriate next step to relieve significant cyanosis in a neonate with d-TGA and a restrictive atrial septum is a balloon atrial septostomy (Rashkind procedure). This procedure tears the atrial septum at the site of the foramen ovale, creating a larger defect that allows for adequate bidirectional mixing of blood and improvement in systemic oxygen saturation. This stabilizes the infant, allowing for the metabolic condition to normalize prior to the definitive corrective surgery, the arterial switch operation.\n\nOption A (Emergent arterial switch operation) is the definitive treatment, but performing major open-heart surgery on a severely hypoxic/unstable neonate carries higher risks. Stabilization via septostomy is preferred first.\nOption C (ECMO) is reserved for cardiorespiratory failure refractory to other measures; septostomy is the specific intervention for the anatomical problem presenting here.\nOption D (Inhaled nitric oxide) decreases pulmonary vascular resistance but does not alleviate the restriction at the atrial septum; increasing pulmonary blood flow without an adequate exit from the left atrium (restrictive PFO) can exacerbate left atrial hypertension and pulmonary edema.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-005", "question": "A 48-year-old woman is brought to the emergency department after being found unresponsive at home. She has a history of depression. On examination, she is comatose with pinpoint pupils, respiratory rate of 6/min, temperature 35.8°C, and blood pressure 90/60 mmHg. ECG shows QRS duration of 145 ms with a terminal R wave in aVR of 4 mm. After securing the airway and administering naloxone without response, what is the most appropriate next intervention?", "options": ["Intravenous flumazenil 0.2 mg", "Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55", "Intravenous lipid emulsion 20% bolus", "Intravenous glucagon 5 mg bolus", "Emergent hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation (coma, miosis, respiratory depression, hypotension) with ECG findings of QRS widening >100 ms and terminal R wave in aVR >3 mm is classic for tricyclic antidepressant (TCA) toxicity. The sodium channel blockade causing cardiac toxicity is treated with sodium bicarbonate, which increases extracellular sodium (overcoming channel blockade) and alkalinizes serum (increasing protein binding of TCA). Target pH is 7.50-7.55. Flumazenil (A) is contraindicated as it may precipitate seizures in TCA overdose. Lipid emulsion (C) is second-line. Glucagon (D) is for beta-blocker toxicity. Hemodialysis (E) is ineffective for TCAs due to high protein binding and large volume of distribution.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "topics_mapped", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "B", "model_outputs": "Based on the clinical presentation and, most critically, the ECG findings, the patient is suffering from Tricyclic Antidepressant (TCA) toxicity.\n\n1.  Diagnosis: The patient has a history of depression and presents with coma. While pinpoint pupils and respiratory depression often suggest opioid toxicity, the lack of response to naloxone makes this less likely to be the primary driver. The pathognomonic features here are the ECG findings:\n    *   QRS duration of 145 ms: Indicates significant sodium channel blockade. A QRS > 100 ms is associated with an increased risk of seizures, and > 160 ms is associated with ventricular arrhythmias.\n    *   Terminal R wave in aVR of 4 mm: A prominent R wave (> 3 mm) in lead aVR is a sensitive and specific sign of sodium channel poisoning, classically seen in TCA overdose.\n\n2.  Management:\n    *   Option B (Sodium bicarbonate) is the first-line treatment for TCA-induced cardiac toxicity. It works by increasing serum pH (alkalinization) and increasing extracellular sodium concentration. Alkalinization promotes the non-ionized form of the drug, reducing its binding to sodium channels, while the sodium load helps overcome the blockade. The therapeutic goal is typically to narrow the QRS complex and maintain a serum pH between 7.50 and 7.55.\n    *   Option A (Flumazenil) is contraindicated. It reverses benzodiazepines but can precipitate seizures, particularly in patients who have co-ingested pro-convulsant agents like TCAs.\n    *   Option C (Intravenous lipid emulsion) is generally reserved for refractory cases of lipophilic drug toxicity (e.g., local anesthetics, severe TCA toxicity unresponsive to bicarbonate) and is not the first-line intervention here.\n    *   Option D (Glucagon) is the antidote for beta-blocker and calcium channel blocker toxicity, not sodium channel blocker toxicity.\n    *   Option E (Hemodialysis) is ineffective because TCAs are highly protein-bound and have a large volume of distribution.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-006", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "obstetrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed126.jsonl", "pred": "D", "model_outputs": "This patient presents with pulmonary edema in the setting of severe preeclampsia with echocardiographic findings of preserved ejection fraction (EF 65%), grade III diastolic dysfunction, and elevated left ventricular filling pressures (E/e' ratio of 18).\n\n1.  Rule out Systolic Heart Failure (Option A): The patient's ejection fraction is 65%, which is normal. Peripartum cardiomyopathy typically presents with reduced ejection fraction (<45%).\n2.  Rule out Volume Overload (Option C): The central venous pressure (CVP) is 4 mmHg, which is on the lower end of normal. This argues against significant intravascular volume overload as the primary cause.\n3.  Evaluate Capillary Permeability (Option B): While endothelial dysfunction in preeclampsia leads to increased capillary permeability and reduced oncotic pressure, the specific echocardiographic finding of an elevated E/e' ratio (18) indicates significantly elevated left ventricular end-diastolic pressure (LVEDP) and left atrial pressure. This points to a hydrostatic cause for the pulmonary edema rather than purely non-cardiogenic edema.\n4.  Analyze Diastolic Dysfunction (Option D): Preeclampsia is characterized by severe vasoconstriction and increased systemic vascular resistance (increased afterload). The left ventricle, facing this acute increase in afterload, may fail to relax appropriately (diastolic dysfunction), leading to elevated filling pressures (evidenced by the high E/e') despite preserved systolic function. This \"afterload mismatch\" results in the retrograde transmission of pressure into the pulmonary circulation, causing pulmonary edema. The low CVP is consistent with a volume-contracted state common in severe preeclampsia, further supporting that the edema is due to left-sided pump mechanics (stiffness/afterload) rather than right-sided or total volume overload.\n\nTherefore, the pathophysiologic mechanism best explaining the pulmonary edema, given the elevated LV filling pressures and preserved EF, is diastolic dysfunction resulting from the heart's inability to handle the high afterload.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-007", "question": "A 35-year-old woman with no psychiatric history presents with acute onset of bizarre behavior, visual hallucinations, and seizures over 3 days. She has no fever. MRI brain shows bilateral medial temporal lobe T2 hyperintensities. CSF analysis reveals lymphocytic pleocytosis (45 cells/μL), elevated protein (68 mg/dL), and normal glucose. EEG shows extreme delta brush pattern. Anti-NMDA receptor antibodies return positive in CSF. CT of chest, abdomen, and pelvis reveals a 4-cm right ovarian mass. After tumor resection (pathology confirms ovarian teratoma), she receives first-line immunotherapy with high-dose corticosteroids, IVIG, and plasmapheresis. At week 6, she remains comatose with persistent seizures. Which of the following is the most appropriate next step in management?", "options": ["Continue current immunotherapy regimen for additional 6 weeks", "Initiate rituximab 375 mg/m² weekly for 4 doses", "Initiate cyclophosphamide 750 mg/m² monthly", "Initiate rituximab and cyclophosphamide combination therapy", "Initiate intrathecal methotrexate"], "answer": "D", "answer_index": 3, "explanation": "Anti-NMDA receptor encephalitis refractory to first-line therapy (tumor removal, corticosteroids, IVIG, and/or plasmapheresis) requires escalation to second-line immunotherapy. Current evidence and expert consensus support combination rituximab and cyclophosphamide as second-line therapy for refractory cases, as this combination targets both B-cell mediated antibody production and provides broader immunosuppression. Using either agent alone is less effective in severe refractory cases. Continuing first-line therapy alone when there is no response at 6 weeks delays effective treatment. Intrathecal methotrexate is not standard therapy for autoimmune encephalitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed128-015", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed128.jsonl", "pred": "B", "model_outputs": "This patient presents with a classic case of anti-NMDA receptor encephalitis, characterized by psychiatric symptoms, seizures, autonomic instability, and a \"delta brush\" pattern on EEG. The presence of an ovarian teratoma confirms the paraneoplastic etiology. Management involves tumor resection and immunotherapy.\n\nCurrent Status: The patient has failed first-line immunotherapy (corticosteroids, IVIG, plasmapheresis) and tumor resection, as she remains comatose with seizures 6 weeks into the clinical course.\n\nManagement Guidelines:\n1.  First-line therapy: Tumor resection (where applicable), corticosteroids, IVIG, and/or plasma exchange.\n2.  Assessment: Response is typically evaluated after 2–4 weeks. If there is no significant clinical improvement, prompt escalation to second-line therapy is recommended.\n3.  Second-line therapy: The standard second-line agents are rituximab (a monoclonal antibody against CD20 on B-cells) or cyclophosphamide (an alkylating agent).\n\nDecision between Options:\n*   A (Continue current): Incorrect. The patient has failed this regimen, and delaying escalation leads to worse outcomes.\n*   B (Initiate rituximab): Correct. Rituximab is the most widely accepted initial second-line agent. It is preferred over cyclophosphamide in young women (childbearing age) due to the significant risk of infertility/premature ovarian failure associated with cyclophosphamide. The dosing listed (375 mg/m² weekly for 4 doses) is the standard protocol.\n*   C (Initiate cyclophosphamide): While effective, its toxicity profile (gonadal toxicity, hemorrhagic cystitis, malignancy risk) makes it a less favorable choice than rituximab for a 35-year-old woman as the initial second-line monotherapy.\n*   D (Initiate rituximab and cyclophosphamide combination): While combination therapy is sometimes used in very severe, refractory cases (often defined as failing rituximab or fulminant disease), the standard \"next step\" in board examinations and most clinical algorithms—prioritizing safety and efficacy—is to maximize rituximab first, especially given the fertility concerns.\n*   E (Intrathecal methotrexate): This is generally considered a third-line or alternative therapy for highly refractory cases.\n\nTherefore, the most appropriate next step, balancing efficacy with the patient's demographic safety profile, is to initiate rituximab.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-008", "question": "A 62-year-old man with longstanding type 2 diabetes presents with a 6-month history of burning pain and numbness in his feet, now extending to mid-calf. Examination reveals absent ankle reflexes, reduced pinprick and vibration sense to the knees bilaterally, and mild weakness of toe extension. Nerve conduction studies show absent sural sensory responses, reduced peroneal motor amplitudes with mildly slowed conduction velocities, and prolonged F-wave latencies. Hemoglobin A1c is 7.2%. He is started on duloxetine with minimal improvement after 8 weeks. Gabapentin is added and titrated to 1800 mg daily with partial response. Which additional intervention has the strongest evidence for further symptomatic improvement?", "options": ["Alpha-lipoic acid 600 mg IV daily for 3 weeks", "Topical capsaicin 8% patch application to affected areas", "Spinal cord stimulation trial", "Transcutaneous electrical nerve stimulation (TENS)", "Acupuncture twice weekly for 12 weeks"], "answer": "C", "answer_index": 2, "explanation": "This patient has painful diabetic peripheral neuropathy refractory to first-line (duloxetine) and second-line (gabapentin) pharmacotherapy. Spinal cord stimulation (SCS) has Level 1 evidence from randomized controlled trials (SENZA-PDN, others) demonstrating significant pain reduction in refractory painful diabetic neuropathy, with FDA approval for this indication. Alpha-lipoic acid (A) has modest evidence primarily from European studies. High-concentration capsaicin (B) provides temporary relief but evidence in diabetic neuropathy is limited. TENS (D) and acupuncture (E) have weaker evidence compared to SCS for refractory cases.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "C", "model_outputs": "The patient has painful diabetic neuropathy (PDN) that has been refractory to first-line pharmacotherapy (Duloxetine) and partially responsive to a second agent (Gabapentin). The options provided include Alpha-lipoic acid IV, Capsaicin 8% patch, Spinal cord stimulation (SCS) trial, TENS, and Acupuncture.\n\n1.  Alpha-lipoic acid (Option A): While the AAN 2011 guidelines assign a Level B recommendation to IV alpha-lipoic acid (600 mg daily for 3 weeks) based on older trials (e.g., SYDNEY), this regimen is impractical for long-term maintenance in most clinical settings and is not considered standard of care in the US. Oral formulations have shown inconsistent results (e.g., NATHAN 1 study).\n2.  Topical Capsaicin 8% patch (Option B): The 8% capsaicin patch (Qutenza) is FDA-approved for PDN. Clinical trials (e.g., STEP) have demonstrated statistically significant pain reduction compared to placebo. However, the effect size is generally modest (e.g., ~30% responder rates or modest reductions in average pain scores relative to placebo).\n3.  Spinal Cord Stimulation trial (Option C): High-frequency (10-kHz) SCS has recently emerged as a highly effective treatment for PDN refractory to medical management. The SENZA-PDN randomized clinical trial (published in *JAMA Neurology*, 2021) compared 10-kHz SCS plus conventional medical management (CMM) to CMM alone. The study showed a profound difference in responder rates (≥50% pain relief) at 3 months: 79% in the SCS group versus 5% in the CMM group. This represents very strong Level 1 evidence with a large effect size specifically for patients who, like this man, have symptoms refractory to Gabapentinoids and SNRIs.\n4.  TENS (Option D) and Acupuncture (Option E): Evidence for these modalities is generally considered weaker, inconsistent, or adjunctive compared to the robust data now available for SCS in this population.\n\nGiven the strength of the recent RCT data demonstrating substantial symptomatic improvement in medically refractory PDN, a spinal cord stimulation trial represents the intervention with the strongest evidence for improvement among the choices listed.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-009", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "topics_mapped", "source_label_raw": "Pediatrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed126.jsonl", "pred": "D", "model_outputs": "This patient presents with signs and symptoms characteristic of PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis).\n\nKey features supporting this diagnosis include:\n1.  Clinical Triad: Along with recurrent fever, the patient has aphthous stomatitis, pharyngitis, and cervical adenitis.\n2.  Regular Periodicity: Fevers occur regularly every 4-6 weeks.\n3.  Onset: Early childhood (age 2).\n4.  Inter-critical Health: The child is completely healthy with normal growth between episodes.\n5.  Exclusion: Genetic testing for other hereditary periodic fever syndromes (FMF, TRAPS, HIDS) is negative.\n\nBased on the diagnosis of PFAPA, let's evaluate the treatment options regarding their likelihood of inducing complete remission (cessation of episodes):\n\n*   A. Colchicine prophylaxis: While effective for Familial Mediterranean Fever (FMF), colchicine has variable and generally modest efficacy in preventing PFAPA attacks.\n*   B. Anakinra: IL-1 blockade is sometimes used for refractory cases, but it is not the standard treatment for inducing permanent remission in typical PFAPA.\n*   C. Single-dose corticosteroid: Administering prednisone or betamethasone at the onset of fever is highly effective at aborting an individual attack. However, it does not cure the syndrome and often leads to a shortening of the interval between episodes (making them more frequent).\n*   D. Tonsillectomy with or without adenoidectomy: Clinical studies and randomized controlled trials have demonstrated that tonsillectomy is highly effective for PFAPA syndrome. It has the highest likelihood of inducing complete remission (cure rates often cited between 60% and nearly 100%).\n*   E. Cimetidine prophylaxis: Cimetidine has been used with some success (roughly 30%), but it is far less effective than surgery for achieving complete resolution.\n\nTherefore, tonsillectomy is the intervention most likely to result in the permanent resolution of symptoms.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p05", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p05-010", "question": "A 6-year-old boy presents with recurrent episodes of weakness and dark urine following viral illnesses. Laboratory studies during an acute episode show: serum creatine kinase 45,000 U/L, myoglobinuria, and non-ketotic hypoglycemia with inappropriately low free fatty acids. Acylcarnitine profile shows elevated C14:1 and C14:2 species. Genetic testing confirms compound heterozygous mutations in ACADVL. Which of the following dietary modifications is most critical for preventing future metabolic crises?", "options": ["Strict avoidance of medium-chain triglycerides", "Supplementation with odd-chain fatty acids", "Restriction of long-chain fatty acids with medium-chain triglyceride supplementation", "High-protein diet with branched-chain amino acid supplementation", "Carnitine supplementation with unrestricted fat intake"], "answer": "C", "answer_index": 2, "explanation": "ACADVL mutations cause very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, a disorder of long-chain fatty acid oxidation. Management requires restriction of long-chain fatty acids (which cannot be metabolized) and supplementation with medium-chain triglycerides (MCTs), which bypass the defective enzyme and provide an alternative energy source. MCT avoidance would be harmful. Carnitine supplementation alone without dietary modification is insufficient, and high-protein diets do not address the underlying metabolic defect.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "topics_mapped", "source_label_raw": "Pediatrics", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed127", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed127.jsonl", "pred": "C", "model_outputs": "The clinical presentation and laboratory findings are characteristic of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCADD).\n\n1.  Diagnosis:\n    *   Clinical: Recurrent rhabdomyolysis (high CK, myoglobinuria, dark urine) triggered by metabolic stress (viral illness), often accompanied by non-ketotic hypoglycemia (inability to generate ketones from fat during fasting).\n    *   Acylcarnitine Profile: Elevated C14:1 (tetradecenoylcarnitine) is the pathognomonic marker for VLCADD.\n    *   Genetics: Mutations in the *ACADVL* gene confirm the diagnosis.\n\n2.  Pathophysiology:\n    *   VLCAD is responsible for the dehydrogenation of long-chain fatty acids (C14 to C20) within the mitochondria.\n    *   A deficiency prevents the breakdown of these fats, leading to energy failure (hypoglycemia) and accumulation of toxic intermediates (rhabdomyolysis, cardiomyopathy).\n\n3.  Dietary Management:\n    *   Restriction of Long-Chain Fatty Acids (LCTs): Since the patient cannot metabolize long-chain fats, dietary intake of typical fats (which are mostly LCTs) must be restricted to prevent the accumulation of toxic acylcarnitines and to reduce the metabolic burden on the blocked pathway.\n    *   Supplementation with Medium-Chain Triglycerides (MCTs): MCTs (C6–C12) enter the mitochondria independently of the carnitine shuttle and are metabolized by Medium-Chain Acyl-CoA Dehydrogenase (MCAD), bypassing the enzymatic block at VLCAD. This provides an essential alternative energy source.\n    *   Avoidance of fasting is also crucial.\n\nAnalysis of Options:\n*   A: Incorrect. MCTs are permissible and beneficial.\n*   B: Incorrect. While triheptanoin (an odd-chain MCT) is used for LC-FAODs, the fundamental dietary modification is LCT restriction with MCT supplementation. \"Odd-chain fatty acids\" is less specific and LCT restriction is key.\n*   C: Correct. This option describes the standard dietary therapy: restricting the substrate the body cannot process (LCT) and providing a substrate it can (MCT).\n*   D: Incorrect. This describes the management for disorders of amino acid metabolism (e.g., MSUD or Urea Cycle Disorders), not fatty acid oxidation disorders.\n*   E: Incorrect. Unrestricted fat intake would be harmful as it introduces high levels of LCTs.\n\nThe answer is (C)"}]